uploads///ousa chea  unsplash

How AstraZeneca Performed in 4Q17 and Fiscal 2017

By

Feb. 28 2018, Published 5:38 p.m. ET

Astra Zeneca revenue trends

In 4Q17, AstraZeneca (AZN) reported revenues of $5.8 billion, which reflected ~3.0% growth on a year-over-year (or YoY) basis and an ~7.0% decline on a quarter-over-quarter basis. In 4Q17, AstraZeneca generated revenues of $5.5 billion from product sales and $290.0 million in externalization revenues.

In fiscal 2017, AstraZeneca reported revenues of $22.5 billion, which is an ~2.0% YoY decline. In 2017, AstraZeneca reported revenues of ~$20.2 billion from product sales while its externalization revenues totaled $2.3 billion. In 2017, AstraZeneca’s externalization revenues witnessed 37.0% YoY growth.

 

In 2017, AstraZeneca’s CVMD (cardiovascular and metabolic disease) drugs Brilinta and Farxiga witnessed 29.0% and 28.0% YoY growth, respectively. AstraZeneca’s major oncology drugs witnessed steady growth, which pushed the company’s product sales.

In 4Q17, AstraZeneca reported its core operating profit and core earnings per share (or EPS) of $1.7 billion and $1.30, respectively, which reflected ~12.0% decline and 7.0% growth on a YoY basis.

In fiscal 2017, AstraZeneca reported a core operating profit and EPS of $6.86 billion and $4.28, respectively, which is ~2.0% growth and 1.0% decline on a YoY basis.

Article continues below advertisement

Regional revenue trends

In 4Q17, in the US and Europe markets, AstraZeneca generated revenues of $1.8 billion and $1.3 billion, respectively, which reflected ~9.0% growth and 3.0% decline on a YoY basis.

In 4Q17, in the emerging markets, AstraZeneca generated revenues of $1.6 billion for ~10.0% growth on a YoY basis. In 4Q17, in China, AstraZeneca reported revenues of $813.0 million and revenues of $817.0 million in emerging markets such as Brazil, India, Mexico, Russia, and Turkey.

In 4Q17, in Japan, AstraZeneca generated revenues of $563.0 million which is ~10.0% growth on a YoY basis.

In the US, Europe, China, and Japan, AstraZeneca reported 2017 revenues of $6.2 billion, $4.8 billion, $3.0 billion, and $2.2 billion, respectively. These revenues reflected respective YoY growth of ~31.0%, ~24.0%, ~15.0%, and ~11.0%.

Expense trends

In fiscal 2017, AstraZeneca reported R&D (research and development) and SG&A (selling, general, and administrative) expenses of $5.8 billion and $10.2 billion, respectively, which reflected an ~2.0% decline and 9.0% growth on a YoY basis.

In 2017, AstraZeneca’s peers in the biopharmaceuticals market Eli Lilly (LLY), Bristol-Myers Squibb (BMY), and Amgen (AMGN) reported revenues of $6.1 billion, $5.4 billion, and $5.8 billion, respectively.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.